|
Market Closed -
Bombay S.E.
05:00:50 2026-01-16 am EST
|
5-day change
|
1st Jan Change
|
|
1,175.55 INR
|
-0.92%
|
 |
-2.80%
|
-7.51%
|
|
25-10-30 |
Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,580 From INR1,650, Keeps at Buy
|
MT
| |
25-10-27 |
Choice Equity Upgrades Dr. Reddy's Laboratories to Add from Reduce; Price Target is INR1,380
|
MT
| |
25-10-27 |
Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,650 From INR1,660, Keeps at Buy
|
MT
| |
25-10-27 |
Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,100, Keeps at Underperform
|
MT
| |
25-10-13 |
BNP Paribas Exane Initiates Dr. Reddy's Laboratories at Neutral With $13.18 Price Target
|
MT
| |
25-07-25 |
Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,660 From INR1,575, Keeps at Buy
|
MT
| |
25-07-24 |
Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,100 From INR1,010, Keeps at Underperform
|
MT
| |
25-05-12 |
Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,010 from INR1,170, Keeps at Underperform
|
MT
| |
25-01-27 |
Nomura Adjusts Dr. Reddy's Laboratories' Price Target to INR1,575 From INR1,500, Keeps at Buy
|
MT
| |
25-01-24 |
Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,170 From INR1,210, Keeps at Underperform
|
MT
| |
24-12-20 |
Nomura Upgrades Dr. Reddy's Laboratories to Buy From Neutral, Cuts Price Target to 1,500 Indian Rupees From 6,499 Indian Rupees
|
MT
| |
24-11-06 |
Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,120, Keeps at Underperform
|
MT
| |
24-07-29 |
Dr. Reddy's Rituximab Biosimilar Recommended for Launch by EMA Committee
|
MT
| |
24-07-29 |
Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR5,600 From INR5,010, Keeps at Underperform
|
MT
| |
24-05-08 |
Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR5,010 From INR5,040, Keeps at Underperform
|
MT
| |
24-01-29 |
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $75, Keeps Overweight Rating
|
MT
| |
23-10-30 |
Jefferies Adjusts Dr. Reddy’s Laboratories’ Price Target to INR6,250 From INR6,330, Keeps at Buy
|
MT
| |
23-07-27 |
Jefferies Adjusts Dr. Reddy Laboratories’ to INR6,300 From INR5,600, Keeps at Buy
|
MT
| |
23-06-01 |
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $70 From $67, Maintains Overweight Rating
|
MT
| |
23-01-30 |
Nomura Adjusts Dr Reddy's Laboratories' Price Target to INR5,161 From INR5,552, Keeps at Buy
|
MT
| |
22-10-25 |
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $66 From $69, Reiterates Overweight Rating
|
MT
| |
22-09-12 |
Barclays Adjusts Dr. Reddy's Laboratories' Price Target to $69 from $68, Maintains Overweight Rating
|
MT
| |
22-07-25 |
Barclays Lowers Dr. Reddy's Laboratories' Price Target to $68 From $70, Maintains Overweight Rating
|
MT
| |
22-01-31 |
Nomura Adjusts Dr. Reddy's Laboratories’ Price Target to 5,552 Indian Rupees From 5,856 Indian Rupees, Keeps at Buy
|
MT
| |
21-11-01 |
Barclays Adjusts Price Target on Dr. Reddy's Laboratories to $80 From $78, Maintains Overweight Rating
|
MT
|
No results for this search Select your edition All financial news and data tailored to specific country editions | 
